These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 23202465)
1. An interagency collaboration to facilitate development of filovirus medical countermeasures. Kilgore N; Nuzum EO Viruses; 2012 Oct; 4(10):2312-6. PubMed ID: 23202465 [TBL] [Abstract][Full Text] [Related]
2. Challenges, progress, and opportunities: proceedings of the filovirus medical countermeasures workshop. Hirschberg R; Ward LA; Kilgore N; Kurnat R; Schiltz H; Albrecht MT; Christopher GW; Nuzum E Viruses; 2014 Jul; 6(7):2673-97. PubMed ID: 25010768 [TBL] [Abstract][Full Text] [Related]
8. The Role of Cytokines and Chemokines in Filovirus Infection. Bixler SL; Goff AJ Viruses; 2015 Oct; 7(10):5489-507. PubMed ID: 26512687 [TBL] [Abstract][Full Text] [Related]
9. Filovirus emergence and vaccine development: a perspective for health care practitioners in travel medicine. Sarwar UN; Sitar S; Ledgerwood JE Travel Med Infect Dis; 2011 May; 9(3):126-34. PubMed ID: 21208830 [TBL] [Abstract][Full Text] [Related]
10. Small Animal Models for Evaluating Filovirus Countermeasures. Banadyga L; Wong G; Qiu X ACS Infect Dis; 2018 May; 4(5):673-685. PubMed ID: 29457711 [TBL] [Abstract][Full Text] [Related]
11. Protection against filovirus infection: virus-like particle vaccines. Yang C; Ye L; Compans RW Expert Rev Vaccines; 2008 Apr; 7(3):333-44. PubMed ID: 18393603 [TBL] [Abstract][Full Text] [Related]
12. The structural basis for filovirus neutralization by monoclonal antibodies. King LB; West BR; Schendel SL; Saphire EO Curr Opin Immunol; 2018 Aug; 53():196-202. PubMed ID: 29940415 [TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of serologic cross-reactivity using convalescent sera from filovirus-experimentally infected fruit bats. Schuh AJ; Amman BR; Sealy TS; Flietstra TD; Guito JC; Nichol ST; Towner JS Sci Rep; 2019 Apr; 9(1):6707. PubMed ID: 31040343 [TBL] [Abstract][Full Text] [Related]
14. Advances in virus-like particle vaccines for filoviruses. Warfield KL; Aman MJ J Infect Dis; 2011 Nov; 204 Suppl 3(Suppl 3):S1053-9. PubMed ID: 21987741 [TBL] [Abstract][Full Text] [Related]
15. The role of reverse genetics systems in determining filovirus pathogenicity. Theriault S; Groseth A; Artsob H; Feldmann H Arch Virol Suppl; 2005; (19):157-77. PubMed ID: 16355872 [TBL] [Abstract][Full Text] [Related]
16. Filovirus proteins for antiviral drug discovery: A structure/function analysis of surface glycoproteins and virus entry. Martin B; Hoenen T; Canard B; Decroly E Antiviral Res; 2016 Nov; 135():1-14. PubMed ID: 27640102 [TBL] [Abstract][Full Text] [Related]
17. Filovirus-like particles as vaccines and discovery tools. Warfield KL; Swenson DL; Demmin G; Bavari S Expert Rev Vaccines; 2005 Jun; 4(3):429-40. PubMed ID: 16026254 [TBL] [Abstract][Full Text] [Related]
18. Filovirus proteins for antiviral drug discovery: Structure/function bases of the replication cycle. Martin B; Canard B; Decroly E Antiviral Res; 2017 May; 141():48-61. PubMed ID: 28192094 [TBL] [Abstract][Full Text] [Related]
19. Outbreaks of filovirus hemorrhagic fever: time to refocus on the patient. Bausch DG; Feldmann H; Geisbert TW; Bray M; Sprecher AG; Boumandouki P; Rollin PE; Roth C; J Infect Dis; 2007 Nov; 196 Suppl 2():S136-41. PubMed ID: 17940941 [TBL] [Abstract][Full Text] [Related]
20. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Dye JM; Herbert AS; Kuehne AI; Barth JF; Muhammad MA; Zak SE; Ortiz RA; Prugar LI; Pratt WD Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5034-9. PubMed ID: 22411795 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]